IGF1 and lung carcinoma: The current evidence for the selection of members of the IGF pathway as viable signposts for lung cancer diagnoses is unclear, and the lack of published reports specifically designed to measure IGF pathway family member levels prior to the diagnosis of disease presents an obstacle.